BLINATUMOMAB and DEATH

Overview

DEATH is the #5 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 627 FDA adverse event reports linking BLINATUMOMAB to DEATH. This represents approximately 3.7% of all 16,815 adverse event reports for this drug.

Patients taking BLINATUMOMAB who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

DEATH is moderately reported among BLINATUMOMAB users, representing a notable but not dominant share of adverse events.

Other Side Effects of BLINATUMOMAB

In addition to death, the following adverse reactions have been reported for BLINATUMOMAB:

• PYREXIA — 1,108 reports
• ACUTE LYMPHOCYTIC LEUKAEMIA RECURRENT — 1,041 reports
• CYTOKINE RELEASE SYNDROME — 1,014 reports
• OFF LABEL USE — 689 reports
• NEUROTOXICITY — 560 reports
• DRUG INEFFECTIVE — 408 reports
• HEADACHE — 352 reports
• FEBRILE NEUTROPENIA — 298 reports
• NEUTROPENIA — 298 reports
• THERAPY NON RESPONDER — 274 reports

Other Drugs Associated with DEATH

The following drugs have also been linked to death in FDA adverse event reports:

Does BLINATUMOMAB cause DEATH?

DEATH has been reported as an adverse event in 627 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is DEATH with BLINATUMOMAB?

DEATH accounts for approximately 3.7% of all adverse event reports for BLINATUMOMAB, making it a notable side effect.

What should I do if I experience DEATH while taking BLINATUMOMAB?

If you experience death while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages